Disclosed is the use of an adenosine diphosphate (ADP) or P2Y12 antagonist and a proton pump inhibitor (PPI) for the manufacture of a pharmaceutical composition for treating or preventing a thrombotic disorder in a patient who does not have a symptom of gastrointestinal bleeding or a gastrointestinal ulcer, wherein the pharmaceutical composition is a single unit oral dosage form comprising: an amount of the ADP or P2Y12 antagonist effective to inhibit platelet aggregation, wherein said ADP or P2Y12 antagonist is clopidogrel or a pharmaceutically acceptable salt, ester, solvate, polymorph, hydrate, or enantiomer thereof and an amount of proton pump inhibitor effective to reduce the risk of developing a gastrointestinal disorder associated with said ADP or P2Y12 antagonist, wherein said PPI is omeprazole or a pharmaceutically acceptable salt, ester, solvate, polymorph, hydrate or enantiomer thereof wherein the PPI is enterically coated and wherein the single unit oral dosage form does not include aspirin. Also disclosed is a unit dosage form comprising clopidogrel or pharmaceutically acceptable salt, ester, solvate, polymorph, hydrate or enantiomer thereof and omeprazole, or pharmaceutically acceptable salt, ester, solvate, polymorph, hydrate or enantiomer thereof.
